

C Blake Gilks

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1384286/c-blake-gilks-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

357
papers

26,864
citations

88
h-index

152
g-index

376
ext. papers

31,544
ext. citations

6.9
avg, IF

6.71
L-index

#	Paper	IF	Citations
357	Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 5367-74	12.9	2156
356	ARID1A mutations in endometriosis-associated ovarian carcinomas. <i>New England Journal of Medicine</i> , 2010 , 363, 1532-43	59.2	1208
355	Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. <i>Lancet Oncology</i> , 2011 , 12, 852-61	21.7	883
354	Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. <i>Nature</i> , 2011 , 475, 226-30	50.4	801
353	Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. <i>PLoS Medicine</i> , 2008 , 5, e232	11.6	575
352	Mutation of FOXL2 in granulosa-cell tumors of the ovary. <i>New England Journal of Medicine</i> , 2009 , 360, 2719-29	59.2	551
351	A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 690-5	11.5	351
350	EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. <i>Cell</i> , 2003 , 115, 523-35	56.2	345
349	Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. <i>New England Journal of Medicine</i> , 2012 , 366, 234-42	59.2	332
348	Cancer-Associated Mutations in Endometriosis without Cancer. <i>New England Journal of Medicine</i> , 2017 , 376, 1835-1848	59.2	310
347	Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. <i>PLoS ONE</i> , 2009 , 4, e6412	3.7	285
346	Mucinous tumors of the appendix associated with mucinous tumors of the ovary and pseudomyxoma peritonei. A clinicopathological analysis of 22 cases supporting an origin in the appendix. <i>American Journal of Surgical Pathology</i> , 1991 , 15, 415-29	6.7	276
345	Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer. <i>Cancer</i> , 2017 , 123, 802-813	6.4	267
344	Differences in tumor type in low-stage versus high-stage ovarian carcinomas. <i>International Journal of Gynecological Pathology</i> , 2010 , 29, 203-11	3.2	260
343	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. <i>Lancet Oncology</i> , 2013 , 14, 853-62	21.7	248
342	Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5697-704	2.2	230
341	Adenoma malignum (minimal deviation adenocarcinoma) of the uterine cervix. A clinicopathological and immunohistochemical analysis of 26 cases. <i>American Journal of Surgical Pathology</i> , 1989 , 13, 717-29	6.7	230

340	Use of mutation profiles to refine the classification of endometrial carcinomas. <i>Journal of Pathology</i> , 2012 , 228, 20-30	9.4	227
339	TITAN: inference of copy number architectures in clonal cell populations from tumor whole-genome sequence data. <i>Genome Research</i> , 2014 , 24, 1881-93	9.7	218
338	Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 874-81	6.7	214
337	Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. <i>Nature Genetics</i> , 2016 , 48, 758-67	36.3	209
336	14-3-3 fusion oncogenes in high-grade endometrial stromal sarcoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012 , 109, 929-34	11.5	208
335	Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma. <i>Human Pathology</i> , 2008 , 39, 1239-51	3.7	207
334	The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: a histologically high-grade and clinically aggressive tumor. <i>American Journal of Surgical Pathology</i> , 2012 , 36, 641-53	6.7	205
333	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. <i>Modern Pathology</i> , 2009 , 22, 393-402	9.8	196
332	IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 2538-48	12.9	182
331	Ovarian carcinoma pathology and genetics: recent advances. <i>Human Pathology</i> , 2009 , 40, 1213-23	3.7	181
330	A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary. <i>American Journal of Surgical Pathology</i> , 2009 , 33, 14-21	6.7	181
329	Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. <i>American Journal of Pathology</i> , 2002 , 161, 1557-65	5.8	180
328	Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. <i>American Journal of Obstetrics and Gynecology</i> , 2014 , 210, 471.e1-11	6.4	178
327	Hierarchical clustering analysis of tissue microarray immunostaining data identifies prognostically significant groups of breast carcinoma. <i>Clinical Cancer Research</i> , 2004 , 10, 6143-51	12.9	175
326	Loss of BAF250a (ARID1A) is frequent in high-grade endometrial carcinomas. <i>Journal of Pathology</i> , 2011 , 224, 328-33	9.4	174
325	The disparate origins of ovarian cancers: pathogenesis and prevention strategies. <i>Nature Reviews Cancer</i> , 2017 , 17, 65-74	31.3	168
324	Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. <i>Modern Pathology</i> , 2014 , 27, 128-34	9.8	168
323	Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. <i>Cell</i> , 2018 , 173, 1755-1769.e22	36.2	159

322	Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival. <i>Journal of Clinical Oncology</i> , 2006 , 24, 5637-44	2.2	159
321	Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017 , 3, e173290	13.4	152
320	Cyclin D1 as a diagnostic immunomarker for endometrial stromal sarcoma with YWHAE-FAM22 rearrangement. <i>American Journal of Surgical Pathology</i> , 2012 , 36, 1562-70	6.7	147
319	Assessment of interlaboratory variation in the immunohistochemical determination of estrogen receptor status using a breast cancer tissue microarray. <i>American Journal of Clinical Pathology</i> , 2002 , 117, 723-8	1.9	145
318	FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. <i>American Journal of Surgical Pathology</i> , 2011 , 35, 484-94	6.7	143
317	Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. <i>Nature Genetics</i> , 2017 , 49, 856-865	36.3	141
316	Stromal mast cells in invasive breast cancer are a marker of favourable prognosis: a study of 4,444 cases. <i>Breast Cancer Research and Treatment</i> , 2008 , 107, 249-57	4.4	140
315	Tissue microarrays are an effective quality assurance tool for diagnostic immunohistochemistry. <i>Modern Pathology</i> , 2002 , 15, 1374-80	9.8	135
314	Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2457-63	2.2	134
313	Acute cigarette smoke-induced connective tissue breakdown is mediated by neutrophils and prevented by alpha1-antitrypsin. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2000 , 22, 244-52	5.7	131
312	High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. <i>International Journal of Gynecological Pathology</i> , 2010 , 29, 343-50	3.2	129
311	Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. <i>American Journal of Surgical Pathology</i> , 2008 , 32, 1835-53	6.7	129
310	Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2. <i>Cancer Research</i> , 2006 , 66, 4872-9	10.1	129
309	Prognostic significance of macrophage infiltration in leiomyosarcomas. <i>Clinical Cancer Research</i> , 2008 , 14, 1423-30	12.9	124
308	Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. <i>Cancer Research</i> , 2004 , 64, 5068-73	10.1	124
307	Tissue microarray validation of epidermal growth factor receptor and SALL2 in synovial sarcoma with comparison to tumors of similar histology. <i>American Journal of Pathology</i> , 2003 , 163, 1449-56	5.8	123
306	Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. <i>Journal of Pathology</i> , 2016 , 238, 389-400	9.4	122
305	An Immunohistochemical Algorithm for Ovarian Carcinoma Typing. <i>International Journal of Gynecological Pathology</i> , 2016 , 35, 430-41	3.2	121

304	Diagnosis of ovarian carcinoma cell type is highly reproducible: a transcanadian study. <i>American Journal of Surgical Pathology</i> , 2010 , 34, 984-93	6.7	119
303	Interpretation of P53 Immunohistochemistry in Endometrial Carcinomas: Toward Increased Reproducibility. <i>International Journal of Gynecological Pathology</i> , 2019 , 38 Suppl 1, S123-S131	3.2	119
302	Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. <i>American Journal of Surgical Pathology</i> , 2018 , 42, 561-568	6.7	117
301	Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. <i>American Journal of Clinical Pathology</i> , 2010 , 134, 835-45	1.9	116
300	The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. <i>Journal of Pathology</i> , 2010 , 222, 191-8	9.4	115
299	Gene expression patterns and gene copy number changes in dermatofibrosarcoma protuberans. <i>American Journal of Pathology</i> , 2003 , 163, 2383-95	5.8	115
298	Small-cell carcinoma of the endometrium. A clinicopathological study of sixteen cases. <i>American Journal of Surgical Pathology</i> , 1994 , 18, 364-75	6.7	114
297	BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma. <i>Modern Pathology</i> , 2012 , 25, 740-50	9.8	113
296	Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. <i>Obstetrics and Gynecology</i> , 2013 , 121, 14-24	4.9	111
295	Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. <i>American Journal of Surgical Pathology</i> , 2005 , 29, 281-94	6.7	110
294	Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). <i>Modern Pathology</i> , 2015 , 28, 1101-22	9.8	107
293	Frequency of known gene rearrangements in endometrial stromal tumors. <i>American Journal of Surgical Pathology</i> , 2011 , 35, 1364-72	6.7	105
292	Morphologic spectrum of immunohistochemically characterized clear cell carcinoma of the ovary: a study of 155 cases. <i>American Journal of Surgical Pathology</i> , 2011 , 35, 36-44	6.7	105
291	Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. <i>Gynecologic Oncology</i> , 2010 , 116, 50-6	4.9	105
290	The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. <i>Modern Pathology</i> , 2004 , 17, 690-5	9.8	104
289	IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype. <i>Modern Pathology</i> , 2009 , 22, 469-75	9.8	102
288	Amplification of 11q13 in ovarian carcinoma. <i>Genes Chromosomes and Cancer</i> , 2008 , 47, 481-9	5	101
287	Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. <i>International Journal of Gynecological Pathology</i> , 2004 , 23, 129-37	3.2	100

286	Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. <i>British Journal of Cancer</i> , 2018 , 119, 1401-1409	8.7	100
285	Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes. <i>Oncotarget</i> , 2015 , 6, 37663-77	3.3	98
284	Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. <i>Journal of Pathology</i> , 2011 , 223, 567-73	9.4	98
283	Chromosomal instability in fallopian tube precursor lesions of serous carcinoma and frequent monoclonality of synchronous ovarian and fallopian tube mucosal serous carcinoma. <i>Gynecologic Oncology</i> , 2008 , 110, 408-17	4.9	98
282	Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. <i>Cancer</i> , 2005 , 103, 1770-7	6.4	98
281	Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular pathologic data. <i>International Journal of Gynecological Pathology</i> , 2004 , 23, 200-5	3.2	97
280	Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1656-62	2.2	95
279	An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. <i>Laboratory Investigation</i> , 2005 , 85, 1392-404	5.9	95
278	Uterine adenomyomas excluding atypical polypoid adenomyomas and adenomyomas of endocervical type: a clinicopathologic study of 30 cases of an underemphasized lesion that may cause diagnostic problems with brief consideration of adenomyomas of other female genital tract sites. <i>International Journal of Gynecological Pathology</i> , 2000 , 19, 195-205	3.2	95
277	Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy: Earlier prognostic information to guide treatment. <i>Gynecologic Oncology</i> , 2016 , 143, 46-53	4.9	94
276	Endometrial Carcinomas with POLE Exonuclease Domain Mutations Have a Favorable Prognosis. <i>Clinical Cancer Research</i> , 2016 , 22, 2865-73	12.9	93
275	Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. <i>Gynecologic Oncology</i> , 2005 , 96, 684-94	4.9	93
274	Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden. <i>Journal of Pathology</i> , 2015 , 236, 201-9	9.4	92
273	Histotype-genotype correlation in 36 high-grade endometrial carcinomas. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 1421-32	6.7	92
272	Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. <i>Annals of Surgical Oncology</i> , 2007 , 14, 719-29	3.1	91
271	Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 357-64	6.7	88
270	Testing women with endometrial cancer to detect Lynch syndrome. <i>Journal of Clinical Oncology</i> , 2011 , 29, 2247-52	2.2	88
269	The histomorphology of Lynch syndrome-associated ovarian carcinomas: toward a subtype-specific screening strategy. <i>American Journal of Surgical Pathology</i> , 2014 , 38, 1173-81	6.7	87

268	ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. <i>Modern Pathology</i> , 2014 , 27, 255-61	9.8	86
267	The fibromatosis signature defines a robust stromal response in breast carcinoma. <i>Laboratory Investigation</i> , 2008 , 88, 591-601	5.9	86
266	Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas. <i>Modern Pathology</i> , 2016 , 29, 302-14	9.8	85
265	Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. <i>American Journal of Surgical Pathology</i> , 2005 , 29, 295-304	6.7	85
264	Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. <i>Histopathology</i> , 2014 , 64, 1004-13	7.3	84
263	Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. <i>Clinical Cancer Research</i> , 2017 , 23, 4086-4094	12.9	83
262	Clinicopathological and molecular characterisation of multiple-classifier endometrial carcinomas. <i>Journal of Pathology</i> , 2020 , 250, 312-322	9.4	83
261	Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. <i>Breast Cancer Research and Treatment</i> , 2008 , 110, 417-26	4.4	82
260	Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality. <i>Journal of the National Cancer Institute</i> , 2016 , 108, djv428	9.7	81
259	Immunolocalization of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and type I GnRH receptor during follicular development in the human ovary. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 4562-70	5.6	80
258	Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models. <i>Gynecologic Oncology</i> , 2005 , 96, 48-55	4.9	80
257	High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations. <i>International Journal of Gynecological Pathology</i> , 2019 , 38 Suppl 1, S40-S63	3.2	80
256	Calculator for ovarian carcinoma subtype prediction. <i>Modern Pathology</i> , 2011 , 24, 512-21	9.8	79
255	Expression of the insulin-like growth factor I receptor and urokinase plasminogen activator in breast cancer is associated with poor survival: potential for intervention with 17-allylamino geldanamycin. <i>Cancer Research</i> , 2004 , 64, 286-91	10.1	77
254	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2016 , 45, 1619-1630	7.8	77
253	Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. <i>Obstetrics and Gynecology</i> , 2015 , 125, 338-345	4.9	76
252	MicroRNA profiling of BRCA1/2 mutation-carrying and non-mutation-carrying high-grade serous carcinomas of ovary. <i>PLoS ONE</i> , 2009 , 4, e7314	3.7	76
251	Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. <i>International Journal of Gynecological Pathology</i> , 2010 , 29, 99-107	3.2	76

250	Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. <i>Gynecologic Oncology</i> , 2006 , 100, 264-70	4.9	72
249	Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates. <i>Histopathology</i> , 2013 , 62, 59-70	7.3	71
248	The specificity of the FOXL2 c.402C>G somatic mutation: a survey of solid tumors. <i>PLoS ONE</i> , 2009 , 4, e7988	3.7	71
247	A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. <i>Modern Pathology</i> , 2009 , 22, 1519-31	9.8	70
246	Interpretation of somatic POLE mutations in endometrial carcinoma. <i>Journal of Pathology</i> , 2020 , 250, 323-335	9.4	70
245	Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma. <i>American Journal of Pathology</i> , 2009 , 174, 2347-56	5.8	69
244	Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases. <i>International Journal of Gynecological Pathology</i> , 2003 , 22, 29-36	3.2	69
243	Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases. <i>American Journal of Surgical Pathology</i> , 2008 , 32, 955-64	6.7	68
242	Targeted transcriptional repression of Gfi1 by GF11 and GF11B in lymphoid cells. <i>Nucleic Acids Research</i> , 2004 , 32, 2508-19	20.1	67
241	Papillary serous carcinoma of the uterine cervix: a clinicopathologic study of 17 cases. <i>American Journal of Surgical Pathology</i> , 1998 , 22, 113-20	6.7	67
240	Detection of the EWS/WT1 gene fusion by reverse transcriptase-polymerase chain reaction in the diagnosis of intra-abdominal desmoplastic small round cell tumor. <i>American Journal of Surgical Pathology</i> , 1996 , 20, 406-12	6.7	66
239	The role of the fallopian tube in ovarian cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2012 , 10, 296-306	0.6	66
238	Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts. <i>Clinical Cancer Research</i> , 2011 , 17, 783-91	12.9	64
237	Growth factor independence-1 is expressed in primary human neuroendocrine lung carcinomas and mediates the differentiation of murine pulmonary neuroendocrine cells. <i>Cancer Research</i> , 2004 , 64, 6874-82	10.1	64
236	Early stage uterine papillary serous carcinoma of the endometrium. <i>Cancer</i> , 2001 , 91, 752-757	6.4	64
235	Patterns of p53 immunoreactivity in endometrial carcinomas: All or nothing staining is of importance. <i>Histopathology</i> , 2011 , 59, 786-8	7.3	63
234	Stromal CD10 expression in invasive breast carcinoma correlates with poor prognosis, estrogen receptor negativity, and high grade. <i>Modern Pathology</i> , 2007 , 20, 84-9	9.8	63
233	Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. <i>PLoS ONE</i> , 2011 , 6, e21121	3.7	63

232	A Comparison of GATA3, TTF1, CD10, and Calretinin in Identifying Mesonephric and Mesonephric-like Carcinomas of the Gynecologic Tract. <i>American Journal of Surgical Pathology</i> , 2018 , 42, 1596-1606	6.7	63
231	Comparison of clinical schemas and morphologic features in predicting Lynch syndrome in mutation-positive patients with endometrial cancer encountered in the context of familial gastrointestinal cancer registries. <i>Cancer</i> , 2012 , 118, 681-8	6.4	62
230	Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. <i>Cell Cycle</i> , 2013 , 12, 1433-49	4.7	62
229	Rare cancers: a sea of opportunity. <i>Lancet Oncology</i> , 2016 , 17, e52-e61	21.7	60
228	The molecular origin and taxonomy of mucinous ovarian carcinoma. <i>Nature Communications</i> , 2019 , 10, 3935	17.4	59
227	Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas. <i>Modern Pathology</i> , 2016 , 29, 1586-1593	9.8	59
226	Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1 β and oestrogen receptor. <i>Histopathology</i> , 2014 , 64, 585-96	7.3	59
225	The origin of ovarian carcinomas: a developmental view. <i>Gynecologic Oncology</i> , 2008 , 110, 452-4	4.9	59
224	FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. <i>Modern Pathology</i> , 2013 , 26, 860-7	9.8	58
223	Endometrial stromal sarcomas with sex cord differentiation are associated with PHF1 rearrangement. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 514-21	6.7	58
222	Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee/Immunohistochemistry: best practice recommendations for standardization of immunohistochemistry tests. <i>American Journal of Clinical Pathology</i> , 2010 , 133, 354-65	1.9	57
221	NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. <i>Oncogene</i> , 2005 , 24, 7281-9	9.2	57
220	Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study. <i>Histopathology</i> , 2017 , 71, 238-246	7.3	56
219	Interobserver Agreement in Endometrial Carcinoma Histotype Diagnosis Varies Depending on The Cancer Genome Atlas (TCGA)-based Molecular Subgroup. <i>American Journal of Surgical Pathology</i> , 2017 , 41, 245-252	6.7	56
218	Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. <i>Modern Pathology</i> , 2007 , 20, 1156-65	9.8	56
217	p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies. <i>Journal of Pathology</i> , 2020 , 250, 336-345	9.4	56
216	Comparison of molecular abnormalities in vulvar and vaginal melanomas. <i>Modern Pathology</i> , 2014 , 27, 1386-93	9.8	55
215	Uterine leiomyosarcomas: tumor size, mitotic index, and biomarkers Ki67, and Bcl-2 identify two groups with different prognosis. <i>Gynecologic Oncology</i> , 2011 , 121, 328-33	4.9	55

214	MDM2 protein expression is a negative prognostic marker in breast carcinoma. <i>Modern Pathology</i> , 2006 , 19, 69-74	9.8	55
213	Expanding the morphologic spectrum of differentiated VIN (dVIN) through detailed mapping of cases with p53 loss. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 52-60	6.7	54
212	Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy. <i>Gynecologic Oncology</i> , 2008 , 110, 256-64	4.9	54
211	Biomarker-based ovarian carcinoma typing: a histologic investigation in the ovarian tumor tissue analysis consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013 , 22, 1677-86	4	53
210	Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma. <i>International Journal of Gynecological Pathology</i> , 2005 , 24, 147-52	3.2	53
209	Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. <i>Histopathology</i> , 2014 , 65, 149-54	7.3	52
208	Functional proteomic analysis of advanced serous ovarian cancer using reverse phase protein array: TGF-beta pathway signaling indicates response to primary chemotherapy. <i>Clinical Cancer Research</i> , 2010 , 16, 2852-60	12.9	52
207	Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?. <i>Journal of Pathology</i> , 2017 , 243, 26-36	9.4	50
206	Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 1548-57	6.7	50
205	Derangement of the E-cadherin/catenin complex is involved in transformation of differentiated to anaplastic thyroid carcinoma. <i>American Journal of Surgery</i> , 2006 , 191, 581-7	2.7	50
204	Mineral dusts directly induce epithelial and interstitial fibrogenic mediators and matrix components in the airway wall. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998 , 158, 1907-13	10.2	50
203	Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma. <i>Clinical Cancer Research</i> , 2019 , 25, 2537-2548	12.9	50
202	Adult-type granulosa cell tumors and FOXL2 mutation. <i>Cancer Research</i> , 2009 , 69, 9160-2	10.1	49
201	Transitional cell carcinoma of the ovary is related to high-grade serous carcinoma and is distinct from malignant brenner tumor. <i>International Journal of Gynecological Pathology</i> , 2012 , 31, 499-506	3.2	49
200	High-grade serous carcinoma of tubo-ovarian origin: recent developments. <i>Histopathology</i> , 2017 , 71, 339-356	7.3	48
199	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. <i>Human Molecular Genetics</i> , 2015 , 24, 5955-64	5.6	48
198	Ovarian carcinoma diagnosis: the clinical impact of 15 years of change. <i>British Journal of Cancer</i> , 2016 , 115, 993-999	8.7	48
197	Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases. <i>International Journal of Gynecological Pathology</i> , 2004 , 23, 265-72	3.2	47

196	Uterine Serous Carcinomas Frequently Metastasize to the Fallopian Tube and Can Mimic Serous Tubal Intraepithelial Carcinoma. <i>American Journal of Surgical Pathology</i> , 2017 , 41, 161-170	6.7	46
195	Histopathological features of endometrial carcinomas associated with POLE mutations: implications for decisions about adjuvant therapy. <i>Histopathology</i> , 2016 , 68, 916-24	7.3	45
194	Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification. <i>Journal of Pathology: Clinical Research</i> , 2017 , 3, 279-293	5.3	44
193	Identifying Lynch syndrome in patients with ovarian carcinoma: the significance of tumor subtype. <i>Advances in Anatomic Pathology</i> , 2013 , 20, 378-86	5.1	44
192	Kisspeptin and GPR54 immunoreactivity in a cohort of 518 patients defines favourable prognosis and clear cell subtype in ovarian carcinoma. <i>BMC Medicine</i> , 2007 , 5, 33	11.4	44
191	The oncogenic roles of DICER1 RNase IIIb domain mutations in ovarian Sertoli-Leydig cell tumors. <i>Neoplasia</i> , 2015 , 17, 650-60	6.4	43
190	p16 Immunostaining Allows for Accurate Subclassification of Vulvar Squamous Cell Carcinoma Into HPV-Associated and HPV-Independent Cases. <i>International Journal of Gynecological Pathology</i> , 2016 , 35, 385-93	3.2	43
189	Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers. <i>BMC Cancer</i> , 2018 , 18, 347	4.8	42
188	HER-3 overexpression is prognostic of reduced breast cancer survival: a study of 4046 patients. <i>Annals of Surgery</i> , 2010 , 251, 1107-16	7.8	42
187	Molecular Analysis of Mixed Endometrial Carcinomas Shows Clonality in Most Cases. <i>American Journal of Surgical Pathology</i> , 2016 , 40, 166-180	6.7	42
186	Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours. <i>Histopathology</i> , 2016 , 69, 560-9	7.3	42
185	Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma. <i>Gynecologic Oncology</i> , 2019 , 153, 487-495	4.9	41
184	The anti-adhesive mucin podocalyxin may help initiate the transperitoneal metastasis of high grade serous ovarian carcinoma. <i>Clinical and Experimental Metastasis</i> , 2012 , 29, 239-52	4.7	41
183	Interobserver variability in the interpretation of tumor cell necrosis in uterine leiomyosarcoma. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 650-8	6.7	41
182	Cell type- and stage-specific changes in HOXA7 protein expression in human ovarian folliculogenesis: possible role of GDF-9. <i>Differentiation</i> , 2006 , 74, 1-10	3.5	41
181	Major p53 immunohistochemical patterns in in situ and invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation status. <i>Modern Pathology</i> , 2020 , 33, 1595-1605	9.8	40
180	Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics. <i>Histopathology</i> , 2016 , 69, 727-738	7.3	40
179	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. <i>Gynecologic Oncology</i> , 2019 , 154, 441-448	4.9	39

178	Loss of the Notch effector RBPJ promotes tumorigenesis. <i>Journal of Experimental Medicine</i> , 2015 , 212, 37-52	16.6	39
177	Aluminum-induced pulmonary fibrosis: do fibers play a role?. <i>The American Review of Respiratory Disease</i> , 1987 , 136, 176-9		39
176	L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile. <i>British Journal of Cancer</i> , 2018 , 119, 480-486	8.7	38
175	Endometrial Carcinomas With Clear Cells: A Study of a Heterogeneous Group of Tumors Including Interobserver Variability, Mutation Analysis, and Immunohistochemistry With HNF-1 α . <i>International Journal of Gynecological Pathology</i> , 2015 , 34, 323-33	3.2	38
174	Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. <i>Journal of Oncology</i> , 2010 , 2010, 740968	4.5	37
173	Regulation of HSulf-1 expression by variant hepatic nuclear factor 1 in ovarian cancer. <i>Cancer Research</i> , 2009 , 69, 4843-50	10.1	37
172	Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. <i>Modern Pathology</i> , 2002 , 15, 365-71	9.8	37
171	Molecularly Defined Adult Granulosa Cell Tumor of the Ovary: The Clinical Phenotype. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	37
170	Aggressive behavior of stage I ovarian mucinous tumors lacking extensive infiltrative invasion: a report of four cases and review of the literature. <i>International Journal of Gynecological Pathology</i> , 2005 , 24, 205-17	3.2	36
169	Assessment of a new system for primary site assignment in high-grade serous carcinoma of the fallopian tube, ovary, and peritoneum. <i>Histopathology</i> , 2015 , 67, 331-7	7.3	35
168	Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers. <i>Gynecologic Oncology</i> , 2015 , 139, 268-74	4.9	35
167	The secondary Mullerian system, field effect, BRCA, and tubal fimbria: our evolving understanding of the origin of tubo-ovarian high-grade serous carcinoma and why assignment of primary site matters. <i>Pathology</i> , 2015 , 47, 423-31	1.6	35
166	Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer. <i>PLoS ONE</i> , 2008 , 3, e3409	3.7	35
165	Distal upstream tyrosinase S/MAR-containing sequence has regulatory properties specific to subsets of melanocytes. <i>Genesis</i> , 1999 , 25, 40-8		34
164	Biomarker expression in pelvic high-grade serous carcinoma: comparison of ovarian and omental sites. <i>International Journal of Gynecological Pathology</i> , 2011 , 30, 366-71	3.2	32
163	Adopting a Uniform Approach to Site Assignment in Tubo-Ovarian High-Grade Serous Carcinoma: The Time has Come. <i>International Journal of Gynecological Pathology</i> , 2016 , 35, 230-7	3.2	31
162	Histotype classification of ovarian carcinoma: A comparison of approaches. <i>Gynecologic Oncology</i> , 2018 , 151, 53-60	4.9	30
161	Immunohistochemical survey of mismatch repair protein expression in uterine sarcomas and carcinosarcomas. <i>International Journal of Gynecological Pathology</i> , 2014 , 33, 483-91	3.2	30

160	Ovarian cellular fibromas lack FOXL2 mutations: a useful diagnostic adjunct in the distinction from diffuse adult granulosa cell tumor. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 1450-5	6.7	30
159	Vulval squamous cell carcinoma and its precursors. <i>Histopathology</i> , 2020 , 76, 128-138	7.3	30
158	Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification. <i>Gynecologic Oncology</i> , 2020 , 158, 3-11	4.9	29
157	Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. <i>Modern Pathology</i> , 2011 , 24, 277-87	9.8	29
156	Claudin 4 Is differentially expressed between ovarian cancer subtypes and plays a role in spheroid formation. <i>International Journal of Molecular Sciences</i> , 2011 , 12, 1334-58	6.3	29
155	HPV-independent Differentiated Vulvar Intraepithelial Neoplasia (dVIN) is Associated With an Aggressive Clinical Course. <i>International Journal of Gynecological Pathology</i> , 2017 , 36, 507-516	3.2	28
154	CSF1 expression in nongynecological leiomyosarcoma is associated with increased tumor angiogenesis. <i>American Journal of Pathology</i> , 2011 , 179, 2100-7	5.8	28
153	Trichoblastic fibroma. A clinicopathologic study of three cases. <i>American Journal of Dermatopathology</i> , 1989 , 11, 397-402	0.9	28
152	TERT promoter mutation in adult granulosa cell tumor of the ovary. <i>Modern Pathology</i> , 2018 , 31, 1107-1115	6.5	27
151	Cell line and patient-derived xenograft models reveal elevated CDCP1 as a target in high-grade serous ovarian cancer. <i>British Journal of Cancer</i> , 2016 , 114, 417-26	8.7	27
150	Better therapeutic trials in ovarian cancer. <i>Journal of the National Cancer Institute</i> , 2014 , 106, dju029	9.7	27
149	The Chemotherapy Response Score (CRS): Interobserver Reproducibility in a Simple and Prognostically Relevant System for Reporting the Histologic Response to Neoadjuvant Chemotherapy in Tuboovarian High-grade Serous Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2017 , 36, 170-178	3.2	27
148	Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients. <i>Pathology</i> , 2008 , 40, 611-6	1.6	27
147	Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC). <i>Gynecologic Oncology</i> , 2016 , 141, 148-54	4.9	26
146	Frequent Mismatch Repair Protein Deficiency in Mixed Endometrioid and Clear Cell Carcinoma of the Endometrium. <i>International Journal of Gynecological Pathology</i> , 2017 , 36, 555-561	3.2	25
145	The Fallopian Tube Origin and Primary Site Assignment in Extrauterine High-grade Serous Carcinoma: Findings of a Survey of Pathologists and Clinicians. <i>International Journal of Gynecological Pathology</i> , 2017 , 36, 230-239	3.2	25
144	Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions. <i>International Journal of Gynecological Pathology</i> , 2019 , 38, 353-362	3.2	25
143	Frequent NFIB-associated Gene Rearrangement in Adenoid Cystic Carcinoma of the Vulva. <i>International Journal of Gynecological Pathology</i> , 2017 , 36, 289-293	3.2	25

142	Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry. <i>International Journal of Gynecological Pathology</i> , 2013 , 32, 529-35	3.2	25
141	DICER1 and FOXL2 Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors. <i>American Journal of Surgical Pathology</i> , 2019 , 43, 628-638	6.7	25
140	The evolution of endometrial carcinoma classification through application of immunohistochemistry and molecular diagnostics: past, present and future. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018 , 472, 885-896	5.1	24
139	Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor. <i>Breast Cancer Research and Treatment</i> , 2016 , 155, 483-90	4.4	24
138	HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. <i>Reproductive Sciences</i> , 2007 , 14, 605-14	3	24
137	HSulf-1 deficiency dictates a metabolic reprogramming of glycolysis and TCA cycle in ovarian cancer. <i>Oncotarget</i> , 2015 , 6, 33705-19	3.3	24
136	Calibration and Optimization of p53, WT1, and Napsin A Immunohistochemistry Ancillary Tests for Histotyping of Ovarian Carcinoma: Canadian Immunohistochemistry Quality Control (CIQC) Experience. <i>International Journal of Gynecological Pathology</i> , 2016 , 35, 209-21	3.2	24
135	Classification of Extraovarian Implants in Patients With Ovarian Serous Borderline Tumors (Tumors of Low Malignant Potential) Based on Clinical Outcome. <i>American Journal of Surgical Pathology</i> , 2016 , 40, 1155-64	6.7	24
134	Clinical and pathological characterization of endometrial cancer in young women: identification of a cohort without classical risk factors. <i>Gynecologic Oncology</i> , 2015 , 138, 141-6	4.9	23
133	HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation. <i>Archives of Pathology and Laboratory Medicine</i> , 2014 , 138, 1495-502	5	23
132	Thyroid transcription factor-1 (TTF-1) immunoreactivity is an adverse prognostic factor in endometrioid adenocarcinoma of the uterine corpus. <i>Histopathology</i> , 2014 , 64, 840-6	7.3	22
131	HMG2 is commonly expressed in uterine serous carcinomas and is a useful adjunct to diagnosis. <i>Histopathology</i> , 2012 , 60, 547-53	7.3	22
130	New insights into the pathogenesis of ovarian carcinoma: time to rethink ovarian cancer screening. <i>Obstetrics and Gynecology</i> , 2012 , 120, 935-40	4.9	22
129	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). <i>Clinical Cancer Research</i> , 2020 , 26, 5411-5423	12.9	21
128	Current morphologic criteria perform poorly in identifying hereditary leiomyomatosis and renal cell carcinoma syndrome-associated uterine leiomyomas. <i>International Journal of Gynecological Pathology</i> , 2014 , 33, 560-7	3.2	21
127	Oviductal glycoprotein, a new differentiation-based indicator present in early ovarian epithelial neoplasia and cortical inclusion cysts. <i>Gynecologic Oncology</i> , 2004 , 93, 315-9	4.9	21
126	Therapeutic options for mucinous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020 , 156, 552-560	4.9	21
125	Spontaneous pulmonary hemorrhage after thrombolytic therapy for acute myocardial infarction. <i>Chest</i> , 1994 , 106, 1622-4	5.3	20

124	The cell surface mucin podocalyxin regulates collective breast tumor budding. <i>Breast Cancer Research</i> , 2016 , 18, 11	8.3	19
123	FOXL2 402C>G Mutation Can Be Identified in the Circulating Tumor DNA of Patients with Adult-Type Granulosa Cell Tumor. <i>Journal of Molecular Diagnostics</i> , 2017 , 19, 126-136	5.1	19
122	FOXL2 mutation is absent in uterine tumors resembling ovarian sex cord tumors. <i>American Journal of Surgical Pathology</i> , 2015 , 39, 618-23	6.7	19
121	A comparison of p53 and WT1 immunohistochemical expression patterns in tubo-ovarian high-grade serous carcinoma before and after neoadjuvant chemotherapy. <i>Histopathology</i> , 2017 , 71, 736-742	7.3	19
120	DNA methylation-based profiling of uterine neoplasms: a novel tool to improve gynecologic cancer diagnostics. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020 , 146, 97-104	4.9	19
119	Ovarian Cancer in Hereditary Cancer Susceptibility Syndromes. <i>Surgical Pathology Clinics</i> , 2016 , 9, 189-99	3.9	19
118	Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: A Canadian high risk endometrial cancer consortium (CHREC) study. <i>Gynecologic Oncology</i> , 2016 , 141, 559-563	4.9	19
117	Molecular characterization of invasive and in situ squamous neoplasia of the vulva and implications for morphologic diagnosis and outcome. <i>Modern Pathology</i> , 2021 , 34, 508-518	9.8	19
116	The changing landscape of gynaecological cancer diagnosis: implications for histopathological practice in the 21st century. <i>Histopathology</i> , 2017 , 70, 56-69	7.3	18
115	Copy number aberrations in benign serous ovarian tumors: a case for reclassification?. <i>Clinical Cancer Research</i> , 2011 , 17, 7273-82	12.9	18
114	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. <i>Human Genetics</i> , 2016 , 135, 741-56	6.3	18
113	Tea, coffee, and caffeinated beverage consumption and risk of epithelial ovarian cancers. <i>Cancer Epidemiology</i> , 2016 , 45, 119-125	2.8	17
112	Assessment of CK17 as a Marker for the Diagnosis of Differentiated Vulvar Intraepithelial Neoplasia. <i>International Journal of Gynecological Pathology</i> , 2017 , 36, 273-280	3.2	17
111	Beta-catenin expression is prognostic of improved non-small cell lung cancer survival. <i>American Journal of Surgery</i> , 2012 , 203, 654-659	2.7	17
110	Are columnar cell lesions the earliest histologically detectable non-obligate precursor of breast cancer?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2008 , 452, 589-98	5.1	17
109	Clinicopathologic Characteristics of Mesonephric Adenocarcinomas and Mesonephric-like Adenocarcinomas in the Gynecologic Tract: A Multi-institutional Study. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 498-506	6.7	17
108	Hematoxylin and Eosin Counterstaining Protocol for Immunohistochemistry Interpretation and Diagnosis. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2019 , 27, 558-563	1.9	17
107	Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma. <i>Journal of Pathology: Clinical Research</i> , 2020 , 6, 252-262	5.3	16

106	Performance of the pattern-based interpretation of p53 immunohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carcinoma. <i>Histopathology</i> , 2020 , 77, 92-99	7.3	16
105	Endometrial carcinoma: molecular subtypes, precursors and the role of pathology in early diagnosis. <i>Journal of Pathology</i> , 2021 , 253, 355-365	9.4	16
104	Does MMR status in endometrial cancer influence response to adjuvant therapy?. <i>Gynecologic Oncology</i> , 2018 , 151, 76-81	4.9	16
103	Molecular subtyping of mammary-like adenocarcinoma of the vulva shows molecular similarity to breast carcinomas. <i>Histopathology</i> , 2017 , 71, 446-452	7.3	15
102	Synchronous tumours of the female reproductive tract. <i>Pathology</i> , 2018 , 50, 214-221	1.6	15
101	Vulvar Acanthosis With Altered Differentiation (VAAD): Report of a Case With Progression to Poorly Differentiated Carcinoma Over a 5-Yr Period. <i>International Journal of Gynecological Pathology</i> , 2015 , 34, 385-9	3.2	15
100	Adult granulosa cell tumour-like areas occurring in ovarian epithelial neoplasms: report of a case series with investigation of FOXL2 mutation status. <i>Histopathology</i> , 2014 , 64, 626-32	7.3	15
99	Gain of OGP, an estrogen-regulated oviduct-specific glycoprotein, is associated with the development of endometrial hyperplasia and endometrial cancer. <i>Clinical Cancer Research</i> , 2004 , 10, 7958-64	12.9	15
98	Papillary serous carcinoma--a less radio-sensitive subtype of endometrial cancer. <i>Gynecologic Oncology</i> , 2005 , 98, 299-303	4.9	15
97	Synthesis of diagnostic quality cancer pathology images by generative adversarial networks. <i>Journal of Pathology</i> , 2020 , 252, 178-188	9.4	15
96	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. <i>Mayo Clinic Proceedings</i> , 2018 , 93, 307-320	6.4	14
95	Kruppel-like factor 5 is not required for K-RasG12D lung tumorigenesis, but represses ABCG2 expression and is associated with better disease-specific survival. <i>American Journal of Pathology</i> , 2010 , 177, 1503-13	5.8	14
94	Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells. <i>American Journal of Surgical Pathology</i> , 2010 , 34, 1132-8	6.7	14
93	Mitotic arrest of endometrial epithelium after paclitaxel therapy for breast cancer. <i>International Journal of Gynecological Pathology</i> , 2000 , 19, 395-7	3.2	14
92	Evaluation of treatment effects in patients with endometrial cancer and POLE mutations: An individual patient data meta-analysis. <i>Cancer</i> , 2021 , 127, 2409-2422	6.4	14
91	Human epidermal growth factor receptor 2 testing in primary breast cancer in the era of standardized testing: a Canadian prospective study. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3967-73	2.2	13
90	Association of human papilloma virus status and response to radiotherapy in vulvar squamous cell carcinoma. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 100-106	3.5	12
89	A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention. <i>BMC Cancer</i> , 2018 , 18, 254	4.8	12

88	Effects of cigarette smoke on tissue uptake and retention of iron oxide in the guinea pig. <i>The American Review of Respiratory Disease</i> , 1988 , 137, 1382-4		12
87	Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results. <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 353-356	3.5	11
86	Bartholin Gland Carcinoma: Clinicopathologic Features, Including p16 Expression and Clinical Outcome. <i>International Journal of Gynecological Pathology</i> , 2019 , 38, 189-195	3.2	11
85	Early stage uterine papillary serous carcinoma of the endometrium 2001 , 91, 752		11
84	p53 Immunohistochemical patterns in HPV-related neoplasms of the female lower genital tract can be mistaken for TP53 null or missense mutational patterns. <i>Modern Pathology</i> , 2020 , 33, 1649-1659	9.8	10
83	Disease Distribution in Low-stage Tubo-ovarian High-grade Serous Carcinoma (HGSC): Implications for Assigning Primary Site and FIGO Stage. <i>International Journal of Gynecological Pathology</i> , 2018 , 37, 324-330	3.2	10
82	Basal biomarkers nestin and INPP4b identify intrinsic subtypes accurately in breast cancers that are weakly positive for oestrogen receptor. <i>Histopathology</i> , 2017 , 70, 185-194	7.3	10
81	Diagnosis of Ovarian Carcinoma Histotype Based on Limited Sampling: A Prospective Study Comparing Cytology, Frozen Section, and Core Biopsies to Full Pathologic Examination. <i>International Journal of Gynecological Pathology</i> , 2015 , 34, 517-27	3.2	10
80	Luteinized thecomas (thecomatosis) associated with sclerosing peritonitis exhibit positive staining with sex cord markers steroidogenic factor-1 (SF-1) and FOXL2. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 1458-9	6.7	10
79	Utility of a CEA, CD15, calretinin, and CK5/6 panel for distinguishing between mesotheliomas and pulmonary adenocarcinomas in clinical practice. <i>American Journal of Surgical Pathology</i> , 2012 , 36, 1503-8	6.7	10
78	Napsin-A and AMACR are Superior to HNF-1 α in Distinguishing Between Mesonephric Carcinomas and Clear Cell Carcinomas of the Gynecologic Tract. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2020 , 28, 593-601	1.9	10
77	c-KIT Analysis and Targeted Molecular Sequencing of Mesonephric Carcinomas of the Female Genital Tract. <i>American Journal of Surgical Pathology</i> , 2020 , 44, 495-502	6.7	10
76	DICER1 hot-spot mutations in ovarian gynandroblastoma. <i>Histopathology</i> , 2018 , 73, 306-313	7.3	9
75	Lynch syndrome screening in gynaecological cancers: results of an international survey with recommendations for uniform reporting terminology for mismatch repair immunohistochemistry results. <i>Histopathology</i> , 2019 , 75, 813-824	7.3	9
74	Differential diagnosis and clinical relevance of ovarian carcinoma subtypes. <i>Expert Review of Obstetrics and Gynecology</i> , 2013 , 8, 67-82		9
73	Canadian Association of Pathologists-Association canadienne des pathologistes National Standards Committee for High Complexity Testing/Immunohistochemistry: guidelines for the preparation, release, and storage of unstained archived diagnostic tissue sections for immunohistochemistry. <i>American Journal of Clinical Pathology</i> , 2014 , 142, 629-33	1.9	9
72	Cyclical expression of the DNA mismatch repair enzyme hMLH1 in normal endometrium. <i>Fertility and Sterility</i> , 2002 , 78, 195-6	4.8	9
71	Extrauterine high-grade serous carcinomas with bilateral adnexal involvement as the only two disease sites are clonal based on tp53 sequencing results: implications for biology, classification, and staging. <i>Modern Pathology</i> , 2018 , 31, 652-659	9.8	9

70	Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. <i>Clinical Cancer Research</i> , 2020 , 26, 4402-4413	12.9	8
69	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2018 , 47, 450-459	7.8	8
68	Patterns of spread of clear cell ovarian cancer: Case report and case series. <i>Gynecologic Oncology Case Reports</i> , 2013 , 6, 25-7		8
67	Loss of Sprouty2 in human high-grade serous ovarian carcinomas promotes EGF-induced E-cadherin down-regulation and cell invasion. <i>FEBS Letters</i> , 2015 , 589, 302-9	3.8	8
66	It sounded like a good idea at the time. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2012 , 34, 1127-1130		8
65	Development of an evidence-based approach to external quality assurance for breast cancer hormone receptor immunohistochemistry: comparison of reference values. <i>Archives of Pathology and Laboratory Medicine</i> , 2011 , 135, 874-81	5	8
64	Interlaboratory Concordance of ProMisE Molecular Classification of Endometrial Carcinoma Based on Endometrial Biopsy Specimens. <i>International Journal of Gynecological Pathology</i> , 2020 , 39, 537-545	3.2	8
63	Comparison of p53 immunohistochemical staining in differentiated vulvar intraepithelial neoplasia (dVIN) with that in inflammatory dermatoses and benign squamous lesions in the vulva. <i>Histopathology</i> , 2021 , 78, 424-433	7.3	8
62	p53abn Endometrial Cancer: understanding the most aggressive endometrial cancers in the era of molecular classification. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 907-913	3.5	8
61	Low grade serous carcinoma of the peritoneum in a BRCA1 carrier previously diagnosed with a "low-grade serous tubal intra-epithelial carcinoma" (STIC) on risk reducing surgery. <i>Gynecologic Oncology Reports</i> , 2015 , 12, 72-4	1.3	7
60	Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2020 , 157, 12-20	4.9	7
59	Absence of BRCA/FMR1 correlations in women with ovarian cancers. <i>PLoS ONE</i> , 2014 , 9, e102370	3.7	7
58	PODO447: a novel antibody to a tumor-restricted epitope on the cancer antigen podocalyxin 2020 , 8,		7
57	Re-assigning the histologic identities of COV434 and TOV-112D ovarian cancer cell lines. <i>Gynecologic Oncology</i> , 2021 , 160, 568-578	4.9	7
56	Adult-type granulosa cell tumor of the ovary: a FOXL2-centric disease. <i>Journal of Pathology: Clinical Research</i> , 2021 , 7, 243-252	5.3	7
55	Two versus four immunostains for Lynch syndrome screening in endometrial carcinoma. <i>Histopathology</i> , 2019 , 75, 442-445	7.3	6
54	Mismatch repair deficiency and prognostic significance in patients with low-risk endometrioid endometrial cancers. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 783-788	3.5	6
53	Letter to the editor regarding @oh MH, Lassin Y, Miron A et al. High-grade fimbrial-ovarian carcinomas are unified by p53, PTEN and PAX2 expression <i>Modern Pathology</i> , 2011 , 24, 1281-2; author reply 1282-3	9.8	6

52	SV40 early genes induce neoplastic properties in serous borderline ovarian tumor cells. <i>Gynecologic Oncology</i> , 2008 , 111, 125-31	4.9	6
51	Amyloidosis of the Uterine Cervix Presenting as Postmenopausal Bleeding. <i>Obstetrics and Gynecology</i> , 2001 , 98, 966-968	4.9	6
50	Canadian Consensus-based and Evidence-based Guidelines for Benign Endometrial Pathology Reporting in Biopsy Material. <i>International Journal of Gynecological Pathology</i> , 2019 , 38, 119-127	3.2	6
49	Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses. <i>Modern Pathology</i> , 2021 , 34, 194-206	9.8	6
48	Low-grade serous carcinoma (LGSC): A Canadian multicenter review of practice patterns and patient outcomes. <i>Gynecologic Oncology</i> , 2020 , 157, 36-45	4.9	5
47	Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries. <i>Histopathology</i> , 2017 , 71, 1014-1017	7.3	5
46	Improved breast cancer biomarker detection through a simple, high frequency, low cost external proficiency testing program. <i>Pathology</i> , 2010 , 42, 637-42	1.6	5
45	Synchronous and Metachronous Endocervical and Ovarian Neoplasms: A Different Interpretation of HPV Data. <i>American Journal of Surgical Pathology</i> , 2005 , 29, 1687-1689	6.7	5
44	Spontaneous regression of stage IV clear cell carcinoma of the endometrium in a patient with essential thrombocytosis. <i>Gynecologic Oncology</i> , 2001 , 82, 395-9	4.9	5
43	Biological effects of biliary shock wave lithotripsy in swine. <i>Investigative Radiology</i> , 1989 , 24, 366-70	10.1	5
42	Use of Immunohistochemical Markers (HNF-1, Napsin A, ER, CTH, and ASS1) to Distinguish Endometrial Clear Cell Carcinoma From Its Morphologic Mimics Including Arias-Stella Reaction. <i>International Journal of Gynecological Pathology</i> , 2020 , 39, 344-353	3.2	5
41	Artefactual punctate MLH1 staining can lead to erroneous reporting of isolated PMS2 loss. <i>Histopathology</i> , 2018 , 73, 703-705	7.3	5
40	A novel lymphocyte activation antigen present on allospecific primed lymphocytes and defined by the monoclonal antibody VG01. <i>Transplantation</i> , 1988 , 45, 978-84	1.8	4
39	Performance of a HER2 testing algorithm specific for p53-abnormal endometrial cancer. <i>Histopathology</i> , 2021 , 79, 533-543	7.3	4
38	Proteomic analysis of archival breast cancer clinical specimens identifies biological subtypes with distinct survival outcomes.. <i>Nature Communications</i> , 2022 , 13, 896	17.4	4
37	The laboratory score/reference method score ratio (LSRSR) is a novel tool for monitoring laboratory performance in immunohistochemistry proficiency testing of hormone receptors in breast cancer: the CIQC experience. <i>American Journal of Clinical Pathology</i> , 2011 , 136, 67-73	1.9	3
36	Characterization of a novel anti-fatty acid synthase (FASN) antiserum in breast tissue. <i>Modern Pathology</i> , 2008 , 21, 1413-20	9.8	3
35	Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.. <i>Journal of Pathology</i> , 2021 ,	9.4	3

34	The most important discoveries of the past 50 years in gynaecological pathology. <i>Histopathology</i> , 2020 , 76, 6-10	7.3	3
33	Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies. <i>International Journal of Gynecological Pathology</i> , 2022 , 41, 12-19	3.2	3
32	Interpretation of mismatch repair protein expression using obsolete criteria results in discrepancies with microsatellite instability and mutational testing results. Comment on Hechtman et al. <i>Mod Pathol</i> 2020; 33:871-879. <i>Modern Pathology</i> , 2021 , 34, 1031-1032	9.8	3
31	Whole-proteome analysis of mesonephric-derived cancers describes new potential biomarkers. <i>Human Pathology</i> , 2021 , 108, 1-11	3.7	3
30	Endometrial Cancer Presentation and Outcomes Based on Mismatch Repair Protein Expression From a Population-Based Study. <i>International Journal of Gynecological Cancer</i> , 2018 , 28, 1624-1630	3.5	3
29	Pathology of Ovarian Cancer: Recent Insights Unveiling Opportunities in Prevention. <i>Clinical Obstetrics and Gynecology</i> , 2017 , 60, 686-696	1.7	2
28	Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers. <i>Human Pathology</i> , 2019 , 92, 39-47	3.7	2
27	Synchronous carcinomas of endometrium and ovary: A pragmatic approach. <i>Gynecologic Oncology Reports</i> , 2019 , 27, 72-73	1.3	2
26	Proteomic analysis of transitional cell carcinoma-like variant of tubo-ovarian high-grade serous carcinoma. <i>Human Pathology</i> , 2020 , 101, 40-52	3.7	2
25	Case report: an identical twin with Sertoli-Leydig cell tumor. <i>Gynecological Endocrinology</i> , 2018 , 34, 563-566		2
24	High-Grade Serous Carcinoma Involving Fallopian Tube, Ovary and Peritoneum. <i>Surgical Pathology Clinics</i> , 2011 , 4, 375-96	3.9	2
23	Molecular Genetics of Mesenchymal Tumors of the Female Genital Tract. <i>Surgical Pathology Clinics</i> , 2009 , 2, 823-34	3.9	2
22	Targeted Molecular Sequencing of Recurrent and Multifocal Non-HPV-associated Squamous Cell Carcinoma of the Vulva. <i>International Journal of Gynecological Pathology</i> , 2021 , 40, 391-399	3.2	2
21	Should you repeat mismatch repair testing in cases of tumour recurrence? An evaluation of repeat mismatch repair testing by the use of immunohistochemistry in recurrent tumours of the gastrointestinal and gynaecological tracts. <i>Histopathology</i> , 2020 , 76, 521-530	7.3	2
20	Performance Characteristics of Endometrial Sampling in Diagnosis of Endometrial Carcinoma. <i>International Journal of Gynecological Pathology</i> , 2020 , 39, 19-25	3.2	2
19	Practical Guidance for Measuring and Reporting Surgical Margins in Vulvar Cancer. <i>International Journal of Gynecological Pathology</i> , 2020 , 39, 420-427	3.2	2
18	Evaluating the impact of universal Lynch syndrome screening in a publicly funded healthcare system. <i>Cancer Medicine</i> , 2020 , 9, 6507-6514	4.8	2
17	Primary mucinous ovarian neoplasms rarely show germ cell histogenesis. <i>Histopathology</i> , 2021 , 78, 640-643		2

16	Endometrial carcinoma molecular subtype correlates with the presence of lymph node metastases.. <i>Gynecologic Oncology</i> , 2022 , 165, 376-384	4.9	2
15	Ovarian carcinoma histotype in Lynch syndrome. <i>Gynecologic Oncology Reports</i> , 2017 , 20, 140-141	1.3	1
14	Academic and nonacademic laboratories perform equally on CIQC immunohistochemistry proficiency testing. <i>American Journal of Clinical Pathology</i> , 2013 , 140, 55-60	1.9	1
13	Surgical staging of early stage epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2011 , 122, 460-1; author reply 461-2	4.9	1
12	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line. <i>PLoS ONE</i> , 2020 , 15, e0240412	3.7	1
11	Online Training and Self-assessment in the Histopathologic Classification of Endocervical Adenocarcinoma and Diagnosis of Pattern of Invasion: Evaluation of Participant Performance. <i>International Journal of Gynecological Pathology</i> , 2021 , 40, S14-S23	3.2	1
10	Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer. <i>Molecular Pharmaceutics</i> , 2021 , 18, 3464-3474	5.6	1
9	HPV-independent, p53-wild-type vulvar intraepithelial neoplasia: a review of nomenclature and the journey to characterize verruciform and acanthotic precursor lesions of the vulva.. <i>Modern Pathology</i> , 2022 ,	9.8	1
8	SATB2 Expression in Uterine Sarcoma: A Multicenter Retrospective Study. <i>International Journal of Gynecological Pathology</i> , 2021 , 40, 487-494	3.2	0
7	Corded and Hyalinized and Spindled Endometrioid Endometrial Carcinoma: A Clinicopathologic and Molecular Analysis of 9 Tumors Based on the TCGA Classifier. <i>American Journal of Surgical Pathology</i> , 2021 , 45, 1038-1046	6.7	0
6	Immunoreactive Acellular Keratin in Sentinel Lymph Nodes From a Patient With Endometrioid Carcinoma of the Endometrium With Squamous Differentiation: A Case Report of a Potential Diagnostic Pitfall. <i>International Journal of Gynecological Pathology</i> , 2021 , 40, 355-358	3.2	
5	Diagnostic Variation in p53 Usage for Endometrial Carcinoma Diagnosis: Implications for Molecular Subtyping. <i>International Journal of Gynecological Pathology</i> , 2020 , 39, 514-521	3.2	
4	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line 2020 , 15, e0240412		
3	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line 2020 , 15, e0240412		
2	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line 2020 , 15, e0240412		
1	Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line 2020 , 15, e0240412		